Decoy Therapeutics, Inc. (DCOY)
1.22
-0.01
(-0.81%)
USD |
NASDAQ |
Oct 30, 09:35
Decoy Therapeutics Net Income (Quarterly) : -2.374M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.374M |
| March 31, 2026 | -2.225M |
| December 31, 2025 | -8.978M |
| September 30, 2025 | -0.8735M |
| June 30, 2025 | -0.9578M |
| March 31, 2025 | -1.710M |
| December 31, 2024 | -1.464M |
| September 30, 2024 | -0.9721M |
| June 30, 2024 | -1.424M |
| March 31, 2024 | -1.715M |
| December 31, 2023 | -0.8818M |
| September 30, 2023 | -2.443M |
| June 30, 2023 | -3.877M |
| March 31, 2023 | -5.341M |
| December 31, 2022 | -6.371M |
| September 30, 2022 | -14.41M |
| June 30, 2022 | -4.718M |
| December 31, 2021 | -4.105M |
| September 30, 2021 | -3.737M |
| June 30, 2021 | -3.074M |
| March 31, 2021 | -1.852M |
| December 31, 2020 | -1.768M |
| September 30, 2020 | -1.717M |
| June 30, 2020 | -1.784M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.084M |
| December 31, 2019 | -1.882M |
| September 30, 2019 | -2.630M |
| June 30, 2019 | -0.9036M |
| March 31, 2019 | -1.522M |
| December 31, 2018 | -1.092M |
| September 30, 2018 | -0.3074M |
| June 30, 2018 | -9.052M |
| March 31, 2018 | -8.223M |
| December 31, 2017 | -8.029M |
| September 30, 2017 | -9.332M |
| June 30, 2017 | -8.805M |
| March 31, 2017 | -8.268M |
| December 31, 2016 | -7.90M |
| September 30, 2016 | -10.64M |
| June 30, 2016 | -11.36M |
| March 31, 2016 | -9.592M |
| December 31, 2015 | -7.893M |
| September 30, 2015 | -8.153M |
| June 30, 2015 | -7.078M |
| March 31, 2015 | -6.018M |
| December 31, 2014 | -3.742M |
| September 30, 2014 | -1.986M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.2276M |
| Total Expenses (Quarterly) | 2.601M |
| EPS Diluted (Quarterly) | -4.462 |
| Enterprise Value | -7.635M |
| Gross Profit Margin (Quarterly) | 94.02% |
| Profit Margin (Quarterly) | -1.04K% |
| Earnings Yield | -3.88K% |
| Normalized Earnings Yield | -2957.11 |